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Abstract
Background: A multicentre case-control study based on sentinel practitioner surveillance networks from seven European
countries was undertaken to estimate the effectiveness of 2009–2010 pandemic and seasonal influenza vaccines against
medically attended influenza-like illness (ILI) laboratory-confirmed as pandemic influenza A (H1N1) (pH1N1).
Methods and Findings: Sentinel practitioners swabbed ILI patients using systematic sampling. We included in the study
patients meeting the European ILI case definition with onset of symptoms .14 days after the start of national pandemic
vaccination campaigns. We compared pH1N1 cases to influenza laboratory-negative controls. A valid vaccination
corresponded to .14 days between receiving a dose of vaccine and symptom onset. We estimated pooled vaccine
effectiveness (VE) as 1 minus the odds ratio with the study site as a fixed effect. Using logistic regression, we adjusted VE for
potential confounding factors (age group, sex, month of onset, chronic diseases and related hospitalizations, smoking
history, seasonal influenza vaccinations, practitioner visits in previous year). We conducted a complete case analysis
excluding individuals with missing values and a multiple multivariate imputation to estimate missing values. The
multivariate imputation (n=2902) adjusted pandemic VE (PIVE) estimates were 71.9% (95% confidence interval [CI] 45.6–
85.5) overall; 78.4% (95% CI 54.4–89.8) in patients ,65 years; and 72.9% (95% CI 39.8–87.8) in individuals without chronic
disease. The complete case (n=1,502) adjusted PIVE were 66.0% (95% CI 23.9–84.8), 71.3% (95% CI 29.1–88.4), and 70.2%
(95% CI 19.4–89.0), respectively. The adjusted PIVE was 66.0% (95% CI 269.9 to 93.2) if vaccinated 8–14 days before ILI
onset. The adjusted 2009–2010 seasonal influenza VE was 9.9% (95% CI 265.2 to 50.9).
Conclusions: Our results suggest good protection of the pandemic monovalent vaccine against medically attended pH1N1
and no effect of the 2009–2010 seasonal influenza vaccine. However, the late availability of the pandemic vaccine and
subsequent limited coverage with this vaccine hampered our ability to study vaccine benefits during the outbreak period.
Future studies should include estimation of the effectiveness of the new trivalent vaccine in the upcoming 2010–2011
season, when vaccination will occur before the influenza season starts.
Please see later in the article for the Editors’ Summary.
Citation: Valenciano M, Kissling E, Cohen J-M, Oroszi B, Barret A-S, et al. (2011) Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010:
Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study. PLoS Med 8(1): e1000388. doi:10.1371/
journal.pmed.1000388
Academic Editor: Lone Simonsen, George Washington University, United States of America
Received May 25, 2010; Accepted November 22, 2010; Published January 11, 2011
Copyright:  2011 Valenciano et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This project received funding from the European Centre for Disease Prevention and Control (ECDC, http://www.ecdc.europa.eu) through the call for
tender FWC ECDC/07/015. ECDC uses only public money and P. Kramarz and B. C. Cianco (coauthors of the article and working for ECDC) have no conflicts of
interest to declare. P. Kramarz and B. C. Ciancio collaborated with EpiConcept in setting up the system, deciding on study design, and writing the article.
PLoS Medicine | www.plosmedicine.org 1 January 2011 | Volume 8 | Issue 1 | e1000388Competing Interests: J-M Cohen is a direct advisor for the French Minister of Health (MOH). His salary as Head of re ´seau des GROG is financed by the French MOH
(76%) and Institut Pasteur (24%). The Institut Pasteur contribution is funded by a pool of five pharmaceutical firms (Roche, Glaxo SmithKline [GSK], Sanofi Pasteur,
Solvay, Arge `ne). As Head of Open Rome, he is involved in several epidemiological studies that are partially or fully funded by pharmaceutical companies (Sanofi-
Pasteur, GSK, Roche), nonprofit organizations (Mutuelles, Re ´saeu DES France) or public institutions (ECDC, CU Strasbourg). He is a member of Association Mieux
Prescrire and the advisory boards of Novartis, Roche, and Wyeth (free participation, no compensation). During the past five years, he has received travel grants from
Sanofi-Pasteur and Roche. A. Mosnier is a member of the French MOH advisory board on influenza, and adviser for influenza to the French Health Insurance
organization. As coordinator of the Re ´seau des GROG (French Influenza Sentinel network), her salary is funded by MOH (76%) and Institut Pasteur (24%). Institut
Pasteur contribution is funded by a pool of five pharmaceutical firms (GSK, Roche, Sanofi-Pasteur, Solvay, Arge `ne). She is involved, through the other institution with
which she is affiliated and salaried (Open Rome research department), in the coordination or analysis of epidemiological studies partially or fully funded by Roche and
GSK. She is member of the Groupe d’Expertise et d’Information sur la Grippe (GEIG) Scientific Board. During the last five years, she has received travel grants from
Roche for speaking, or participation, at scientific meetings. All other authors have declared that no competing interests exist.
Abbreviations: ARI, acute respiratory infection; CI, confidence interval; EU, European Union; GP, general practitioner; ILI, influenza-like illness; PIVE, pandemic
influenza vaccine effectiveness; SIVE, seasonal influenza vaccine effectiveness; VE, vaccine effectiveness
* E-mail: m.valenciano@epiconcept.fr
Pandemic Vaccine Effectiveness in Europe
PLoS Medicine | www.plosmedicine.org 2 January 2011 | Volume 8 | Issue 1 | e1000388Introduction
Following the World Health Organization’s declaration of
pandemic phase six in June 2009, manufacturers developed
vaccines against pandemic influenza A (H1N1) 2009 (pH1N1). On
the basis of advice from the European Medicine Agency (EMA),
the European Commission initially granted marketing authoriza-
tion for three pandemic vaccines to be used in European Union
(EU) countries. In selected countries including France, Hungary,
and Romania, national regulatory authorities provided a licence
for additional vaccines. Early clinical trials showed that the
pandemic vaccines elicited good immunological responses after the
first dose [1–3]. However, as strong immunogenicity does not
always result in robust vaccine effectiveness (VE), it was important
to estimate the effectiveness of the vaccine at the population level.
In the first months of the pandemic, various studies assessed the
effect of the 2008–2009 seasonal influenza vaccine on pH1N1
related outcomes. The results were controversial: a hospital-based
case-control study in Mexico suggested a protective effect of the
vaccine against pH1N1 hospitalization [4], while studies in
Australia and the United States did not find any effect of 2008–
2009 seasonal influenza vaccine on the risk of medically attended
pH1N1 illness [5,6]. Studies in Canada suggested an increased risk
of pandemic H1N1 infection following receipt of the seasonal
influenza vaccine [7].
During the autumn of 2009, most EU member states included
the 2009–2010 seasonal influenza vaccine and the pandemic
H1N1 influenza vaccine in their influenza vaccination pro-
grammes. The groups targeted by the seasonal and pandemic
vaccination programmes differed among member states. In some
risk groups, both seasonal and pandemic vaccines were recom-
mended.
The Influenza Monitoring Vaccine Effectiveness in Europe (I-
MOVE) network was established with the aim of monitoring
seasonal and pandemic influenza vaccine effectiveness (PIVE) [8].
During the 2008–2009 pilot season, five case-control and two
cohort studies were conducted in six EU member states to estimate
the VE of the 2008–2009 seasonal vaccine [9,10]. Data from the
five pilot case-control studies were pooled to provide an overall
adjusted VE [11].
In 2010, to estimate the PIVE against medically attended
influenza-like illness (ILI) laboratory confirmed as p1H1N1, we
undertook a multicentre case-control study based on sentinel
practitioner surveillance networks from seven study sites (France,
Hungary, Ireland, Italy, Romania, Portugal, and Spain). A
secondary objective of the study was to estimate the effectiveness
of the 2009–2010 seasonal influenza vaccine against medically
attended ILI laboratory confirmed as pH1N1.
Methods
The study was conducted within the context of the existing
European Influenza Surveillance Network (EISN) [12]. At the
seven study sites, EISN sentinel primary care practitioners were
invited to participate in the study. In Portugal and Italy,
practitioners other than those participating in EISN, were also
invited to participate.
The study population consisted of patients consulting a
participating practitioner for ILI (six sites) or acute respiratory
infection (ARI) (France) and having a nasal or throat swab taken
within an interval of less than 8 d after symptom onset. In
Hungary, the study population was restricted to patients aged
more than 17 y. In Italy, the study population was restricted to
patients who belonged to the groups for which the pandemic
vaccine was recommended.
In five of the seven study sites practitioners used a systematic
random sample to select the patients to swab. In Ireland each
participating practice was asked to take a nasal or throat swab
from five patients presenting with ILI each week. In France, each
practitioner had an age group assigned and swabbed the first ARI
patient of the week in the allocated age group.
A case of pandemic influenza A (H1N1) 2009 (pH1N1 case) was
an ILI patient (defined according to the EU case definition as
sudden onset of symptoms and at least one of the following four
systemic symptoms: fever or feverishness, malaise, headache,
myalgia, and at least one of the following three respiratory
symptoms: cough, sore throat, shortness of breath) [13] who was
swabbed and tested positive for the pH1N1 using real-time (RT)
PCR or culture. Controls were ILI patients who were swabbed
and tested negative for any influenza virus.
Swabs were tested for influenza at the respective countries’
National Influenza Reference Laboratory. In France, Italy, and
Spain, tests were also conducted in other laboratories participating
in the National Influenza Sentinel Surveillance System.
For pandemic and seasonal influenza vaccine, individuals were
considered vaccinated if they had received a dose of the vaccine
more than 14 d before the date of onset of ILI symptoms and
unvaccinated if they had received no vaccine or the vaccine was
given less than 15 d before the onset of ILI symptoms. For
pandemic vaccination we also estimated the PIVE among those
vaccinated less than 8 d, those vaccinated between (and including)
8 and 14 d, and those vaccinated more than 14 d before onset of
symptoms compared to those never vaccinated. Participating
sentinel practitioners conducted face-to-face interviews with ILI
patients using pilot-tested country-specific standardised question-
naires. The variables collected included ILI signs and symptoms,
date of onset of symptoms, pandemic and 2009–2010 seasonal
vaccination status including date of vaccination, and a list of
potential confounding factors: age, sex, presence of chronic
condition(s), pregnancy, obesity (not collected in France), severity
of chronic disease using the number of hospitalizations for the
chronic disease(s) in the previous 12 mo as a proxy, smoking
history (nonsmoker, past, current smoker), number of practitioner
visits in the previous 12 mo, influenza antiviral use before
swabbing, and seasonal influenza vaccination in the previous
two seasons. Vaccination status was ascertained using the
practitioners’ medical records or during the patient interview.
Each of the seven study teams entered and validated data.
Validation of the vaccination status and of other variables was
attempted by contacting the practitioner or by checking existing
vaccination registries in the case of missing information.
The study teams sent anonymised databases of ILI cases
recruited to the EpiConcept coordination team. The coordination
team checked the data for inconsistencies, outliers, and logical
errors and created a common dataset restricted to individuals
meeting the EU ILI case definition, with onset of ILI symptoms
more than 14 d after the start of the pandemic vaccination in each
country. For each study site, we included in the common dataset
records up to the week that preceded two consecutive weeks in
which none of the recruited patients tested positive for pH1N1.
We excluded individuals who tested positive for influenza A but
had a nontypeable strain, those testing positive for other strains of
influenza A or for influenza B, and those with missing information
on laboratory results.
We compared the characteristics of cases and controls using the
Fisher exact test or Mann-Whitney test as appropriate. We
estimated the pooled seasonal influenza vaccine effectiveness
(SIVE) and PIVE as 1 minus the odds ratio (OR) using a one-stage
method with the study site as fixed effect in the model. To estimate
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potential confounding factors.
We first conducted the analysis excluding all individuals with
missing values (complete case analysis). We then estimated missing
data for pandemic vaccination status and covariates using the
multiple multivariate imputation by chained equations procedure
in Stata [14]. We used missing at random assumptions. We used
all predictors together to impute the missing values and
independently analysed 20 copies of the data using 30 cycles of
regression.
We stratified the adjusted PIVE and SIVE according to three
age groups (,15, 15–64, and $65 y of age) and the adjusted PIVE
by presence of chronic disease. We split the study period into two
periods (early and late phase) using the date of symptom onset of
the median case in each of the study sites and estimated PIVE for
each of the phases.
We conducted all statistical analysis using Stata version 10.1
(StataCorp LP).
According to country-specific requirements for ethical approval,
all participants provided oral or written consent.
Results
In the seven participating countries, influenza activity peaks
were reached between week 43 (Ireland) and week 50 (Hungary,
Romania) (Figure S1) of 2009. Of the six vaccines used at the
seven study sites, three were adjuvanted (Table S1). The first
country to start a pandemic vaccination campaign was Hungary
(week 40) and the last was Romania (week 48) (Figure S1; Table 1).
A total of 1,114 practitioners agreed to participate in the study.
Within the study period, 699 of the practitioners recruited 2,926
patients who met the EU ILI case definition and who were
swabbed less than 8 d after symptom onset (Table 2). After
excluding 17 individuals with non-subtypeable influenza A, one
positive for influenza B, and six with missing information on
laboratory results, a total of 2,902 ILI patients were included in the
analysis (Figure S2). Among these patients, 918 (31.6%) were
positive for pH1N1 (ranging from 15.2% in Hungary to 38.1% in
France).
197 individuals (6.9%) had received at least one dose of
pandemic vaccine more than 14 d before the date of symptom
onset (ranging from 0.0% in Italy to 29.4% in Hungary). 11 of
them had received two doses. Out of the 197 individuals
vaccinated, vaccine brand was documented for 195. Among
them, 155 (79.5%) had received an adjuvanted vaccine and 40
(20.5%) a nonadjuvanted vaccine.
The median age was lower in cases (12 y) than in controls
(27 y). The delay between onset of symptoms and swabbing was
shorter in cases than in controls (Table 3). The proportion of
individuals presenting with fever, headache, or cough was higher
among cases than among controls. Compared to cases, a higher
proportion of controls had diabetes, heart disease, and were
hospitalised at least once for their chronic disease in the previous
12 mo. A higher proportion of controls were current or past
smokers, vaccinated with the 2009–2010 seasonal influenza
vaccine, and vaccinated against influenza in the previous 2 y.
The median number of practitioner visits in the previous 12 mo
was three for cases (ranging from 0 to 22) and four for controls
(ranging from 0 to 44) (Table 3). A total of 12 pH1N1 cases were
vaccinated with the pandemic vaccine more than 14 d before
symptom onset. Two of these cases were under 15 y of age, three
were 65 y of age or older, and the remaining seven were aged 15
to 64 y. None of the cases had received two doses of the pandemic
vaccine. In two of the seven studies there were no vaccinated
individuals among the recruited cases (Table 2).
Pandemic Vaccine Effectiveness
We included 1,502 individuals in the pooled complete case
analysis. The overall PIVE adjusted for all potential confounding
factors was 66.0%, 71.3% in those aged ,65 y, and 70.2% in
those with no chronic disease (Table 4).
In the pooled analysis with imputed data, we included all 2,902
individuals. The overall PIVE adjusted for all potential confound-
ing factors was 71.9%, 78.4% in those aged ,65 y, and 72.9% in
those with no chronic diseases (Table 4). PIVE was 79.3% (95%
confidence interval [CI] 4.7–95.9) in the early phase and 68.8%
(95% CI 35.8–84.8) in the late phase of the study.
We analysed an intermediate dataset that included 2,073
records after removing those with missing values in the variables
that changed the odds ratio of being vaccinated by more than 5%
in the complete case or multiple imputation analysis (age group,
number of practitioner visits in the previous 12 mo, 2009-2010
seasonal influenza vaccine, and month of symptom onset). The
PIVE adjusted for these variables was 72.4% (95% CI 44.1–86.4)
overall, 80.1% (95% CI 54.8–91.2) in those aged ,65 y, and
73.4% (95% CI 35.6–89.0) in those with no chronic disease.
Using 30 d as the cut off to start the inclusion of ILI patients in
the study instead of 15 d after the start of the vaccination
campaigns did not change the PIVE estimates (Table S6). In the
complete case analysis, taking into account different delays
between date of vaccination and date of onset of ILI symptoms,
Table 1. Timing of key events in the 2009–2010 influenza season relevant to the I-MOVE study.
Country
Week of Maximum
Incidence of ARI
a or ILI
b
Week of Start of Pandemic
Vaccination Campaign
Week of Inclusion of
First ILI Case in the Study
Date of Inclusion of
First ILI Case in the Study
France 49
a 43 45 04/11/2009
Hungary 50
b 40 50 09/12/2009
Ireland 43
b 45 47 17/11/2009
Italy 46
b 43 47 17/11/2009
Portugal 46
b 44 46 12/11/2009
Romania 50
a 48 53 03/01/2010
Spain 46
b 46 48 01/12/2009
aSentinel systems reporting ARIs.
bSentinel systems reporting ILI.
doi:10.1371/journal.pmed.1000388.t001
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14 d (Table 5).
Vaccine Effectiveness of the 2009–2010 Seasonal Vaccine
A total of 296 individuals (10.2%) had received the 2009–2010
seasonal vaccine more than 14 d before the date of symptom onset
(Table 3). The SIVE estimates adjusted for all potential
confounding factors was 9.9% in the complete-case analysis and
21.5% in the multiple imputation analysis (Table 6).
Discussion
Using sentinel practitioner networks in seven EU countries, we
estimated the effectiveness of the 2009–2010 pandemic and
seasonal influenza vaccines. The pooled results suggest that one
dose of a pandemic vaccine conferred good protection against
medically attended pH1N1 ILI (65.5%–100% according to the
various stratified analyses performed). The PIVE was higher in
persons aged ,65 y old and in those without any chronic disease.
Furthermore, the PIVE point estimates suggest a good PIVE as
early as 8 d after vaccination. During the study period, the 2009–
2010 seasonal vaccine seems to have had no effect on pH1N1
illness.
We believe these results should be interpreted with caution for
reasons including the late timing of the studies relative to
pandemic vaccine rollout, low incidence of medically attended
H1N1 illness, low vaccine coverage and potential biases due to the
test-negative design, confounding factors, and missing values.
Pandemic Context
One of the major limitations of the study is the timing of
vaccination during the pandemic. In most participating countries,
the pandemic vaccination campaigns and therefore the recruit-
ment in the study sites started during the pandemic or after the
peak of the pandemic.
As a consequence, part of the population had acquired natural
immunity to the pandemic H1N1 influenza strain before the start
of the studies. If this natural immunity differed between those
who were later vaccinated and those who were not, this could
have biased the PIVE. In particular, if vaccinated persons had a
higher risk of infection before vaccination (e.g., children), we
might have overestimated the PIVE. We may not have totally
controlled for this indication bias by adjusting for age and time of
recruitment. Only a cohort study design including a sero-
prevalence component at the start of the study can help in
quantifying this bias, which is likely to affect all studies conducted
during the pandemic.
Within each country, eligible groups were not offered
vaccination at the same time (Table S2). We could not restrict
our analysis to the time at which individuals became eligible for
vaccination as most sites did not include the necessary information
to identify them. We may therefore have included individuals for
whom vaccination was not or not yet indicated. Consequently, we
may have inflated the number of cases unvaccinated in the early
phase of the study and overestimated the PIVE. The potential
biases introduced by including them cannot be quantified in our
study and should be measured with cohort studies using large
databases. However, the simulations we carried out suggest that
such a bias may be minimal in a situation with low incidence and
low vaccine coverage (unpublished data).
The low incidence of medically attended H1N1 influenza
infection and the low pandemic influenza vaccination coverage in
all study sites (Table S3) led to a small number of vaccinated cases
and limited the statistical power of each of the stratified analyses.
The low vaccination coverage did not allow PIVE estimation by
vaccine brand. We computed PIVE by target groups for
vaccination (age groups, chronic diseases). All estimates were
above 60% but had very large CIs.
We could only estimate the effect of one dose of the pandemic
vaccine because of the small number of individuals who had
received two doses.
In countries where adjuvanted and nonadjuvanted vaccines
were used, each vaccine was recommended for a different target
group and marketed at different times (Tables S1 and S2). It was
not possible to identify different target groups which precluded
estimating effectiveness according to the vaccine type.
Table 2. Practitioners and patient recruitment in the 2009–2010 influenza season relevant to the I-MOVE study.
Study Site
Practitioners
in the
National
Sentinel
System, n
Practitioners
Accepting to
Participate
in the
Study, n
Practitioners
Recruiting at
Least One ILI
Patienta, n
ILI Patientsa
Recruited by
Practitioners,
n
Inclusion
Period for
the Studyb
ILI Patients Included
in the Study Positive
for Influenza A
(H1N1) 2009
c, n
ILI Patients Included
in the Study
Negative for
Influenza A (H1N1)
2009
c, n
Total Vaccinated Total Vaccinated
France 550 550 429 1,908 4/11/2009–28/2/2010 720 3 1,172 63
Hungary 168 87 63 361 8/12/2009–14/3/2010 55 6 306 100
Ireland 137 48 19 77 17/11/2009–10/1/2010 29 1 48 2
Italy 1,163 47 21 69 03/11/2009–13/12/2009 18 0 44 0
Portugal 150 53 32 186 10/11/2009–21/2/2010 31 0 155 10
Romania 270 102 12 24 17/12/2009–31/1/2010 5 1 19 1
Spain 880 227 123 301 01/12/2009–7/2/2010 60 1 240 9
Total 3,318 1,114 699 2,926 918 12 1,984 185
aILI patients meeting the EU case definition, swabbed ,8 d after onset of symptoms within the study period.
bFor each study site, from 15 d after the start of the vaccination campaign up to the week that preceded 2 consecutive weeks in which none of the ILI patients recruited
tested positive for influenza A (H1N1) 2009 recruited. In Hungary, the start of the study period was the week of receiving the agreement from the Ethics Committee.
cILI patients in the study after excluding those having tested previously to pH1N1, those positive to other influenza virus, and those with missing information on
laboratory results.
doi:10.1371/journal.pmed.1000388.t002
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to the study period, which is 15 d after the start of the pandemic
vaccination campaigns. Using 30 d after the start of the pandemic
vaccination campaigns as the study period, did not change the
estimates (Table S6).
Study Design
Our results are based on data from seven European countries
sharing the same protocol and definition of variables. The pooled
data resulted in a sample size with enough power to provide
precise overall crude and adjusted pooled estimates.
Misclassification
We observed shorter delays between onset of symptom and
swabbing in cases than in controls. As the probability of
influenza detection decreases with time since onset [15], we
may have misclassified as controls some influenza cases who
tested negative. If vaccinated cases develop milder illness and
seek medical help later, the vaccination coverage in the control
group will be inflated resulting in a higher PIVE. Similarly, if
unvaccinated cases tend to consult their general practitioner (GP)
later because of their health-seeking behaviour, the PIVE will be
underestimated. On the other hand, because cases are less likely
to be vaccinated, the vaccine coverage among controls will
decrease by having cases misclassified as controls and the
PIVE will be underestimated. Restricting the analysis to ILI
patients tested within 4 d of onset of symptoms, PIVE estimates
did not change (Table S4). In addition, in our studies, 91% of the
ILI patients were swabbed less than 4 d after onset of ILI
symptoms.
Table 3. Pandemic influenza A (H1N1) 2009 cases and test-negative controls included in the study by patient characteristics.
Patient Characteristics Cases n=918 Test-Negative Controls n=1,984 p-Value
Median age, y 12 27 ,0.001
a
Age group, y, n/total n (%)
0–4 180/917 (19.6) 520/1,978 (26.3) ,0.001
b
5–14 326/917 (35.6) 195/1,978 (9.9)
15–64 393/917 (42.9) 1,069/1,978 (54.0)
$65 18/917 (2.0) 194/1,978 (9.8)
Female sex, n/total n (%) 485/912 (53.2) 1,005/1,971 (51.0) 0.279
b
Symptoms, n/total n (%)
Fever 903/918 (98.4) 1,842/1,957 (94.1) ,0.001
b
Headache 611/907 (67.4) 1,194/1,936 (61.7) 0.003
Cough 869/914 (95.1) 1,718/1,964 (87.5) ,0.001
b
Sore throat 539/914 (59.0) 1,340/1,945 (68.9) ,0.001
b
Days between onset of symptoms and swabbing, n/total n (%)
0 111/918 (12.1) 212/1,984 (10.7) ,0.001
b
1 512/918 (55.8) 987/1,984 (49.7)
2 201/918 (21.9) 454/1,984 (22.9)
3 70/918 (7.6) 181/1,984 (9.1)
4 17/918 (1.9) 77/1,984 (3.9)
5 6/918 (0.7) 36/1,984 (1.8)
6 1/918 (0.1) 21/1,984 (1.1)
7 0/918 (0.0) 16/1,984 (0.8)
Diabetes, n/total n (%) 8/690 (1.2) 72/1,670 (4.3) ,0.001
b
Heart disease, n/total n (%) 20/688 (2.9) 198/1,670 (11.9) ,0.001
b
Any hospitalization in the previous 12 mo
for chronic diseases, n/total n (%)
5/680 (0.7) 37/1,739 (2.3) 0.005
b
Smoker, n/total n (%)
Current 35/814 (4.3) 176/1,739 (10.1) ,0.001
b
Former 80/814 (9.8) 244/1,739 (14.0)
Never 699/814 (85.9) 1319/1,739 (75.8)
Pandemic vaccination, n/total n (%) 12/895 (1.3) 185/1,940 (9.5) ,0.001
b
Seasonal vaccination, 2009–2010, n/total n (%) 56/913 (6.1) 240/1,975 (12.2) ,0.001
b
Any influenza vaccination in the previous
two seasons, n/total n (%)
56/516 (10.9) 213/1,316 (16.2) 0.003
b
Median number of GP visits in the previous 12 mo 34 ,0.001
a
aNonparametric test of the median.
bTwo-sided Fisher exact test.
doi:10.1371/journal.pmed.1000388.t003
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In the complete case analysis, we excluded 1,400 individuals
with no information for at least one of the variables (losing one-
third of vaccinated cases).
In the 2,902 observations, the highest proportion of missing
values were for number of visits to a GP in the past 12 mo (27.5%)
and influenza vaccination in the past two seasons (36.9%) (Table
S7). Missing values for certain covariates were associated with the
outcome and with pandemic influenza vaccination (unpublished
data) and therefore we could not assume that our missing values
fell into the category of missing completely at random (MCAR)
[14]. To reduce the potential bias we used a method of multiple
imputation by chained equations procedure in which values are
imputed according to associations observed between many other
variables (including confounders) and the missing variable. We
were able to use a large number of variables for the imputation,
including key variables such as week of symptom onset, outcome,
study site, and vaccination variables. We also conducted the
analysis excluding the 67 individuals with no information about
pandemic vaccination status and the results did not change
(adjusted PIVE 72.9%, 95% CI 46.7–85.6).
The PIVE estimated using the complete case analysis was
slightly lower than the estimates using the dataset with imputed
data (absolute differences ranging from 3.6% to 7.6%). However,
all PIVE point estimates were greater than 65%. Given the smaller
sample size, the PIVE estimates from the complete case analysis
are less precise.
We further checked the outcome of the imputation by
comparing the imputed values for pandemic vaccination against
a validation subset in France (more than 90% of the missing data
coming from France). The proportion vaccinated in the validation
set was similar to the imputed proportion of vaccinated (Chi
2 test
for differences in proportion: p=0.749). Missing values remain a
limitation in observational studies based on surveillance data. The
use of randomly selected validation subsets with additional and
verified information will help controlling for potential biases
because of missing values.
The administration of both trivalent seasonal and monovalent
pandemic vaccine may have made the ascertainment of vaccina-
tion status difficult. In six countries vaccination was mainly done
by practitioners and we believe that they correctly documented
vaccination status. In France, pandemic vaccinations were only
done in pandemic vaccination centres where each individual
received a vaccination card. Patients could remember if they had
been to a pandemic vaccination centre and practitioners could in
addition verify the vaccination cards.
Selection
The test-negative design is a hybrid design approaching a
density case-control study in which the effect measured would be
Table 4. Pooled crude and adjusted PIVE.
Complete Case and
Imputed Data Analysis
Crude and Adjusted
PIVE Estimates Included Population n Percent PIVE 95% CI
Complete case analysis
a Crude
b All 1,502 79.0 55.8–90.0
,65 y 1,367 83.3 61.2–92.8
15–64 y 912 76.6 44.7–90.1
,15 y 455 100 58.2–100.0
c
No chronic disease 1,190 81.5 53.0–92.7
Adjusted model
d All 1502 66.0 23.9–84.8
,65 y 1,367 71.3 29.1–88.4
15–64 y 912 65.5 12.3–86.5
,15 y 455 100 Not calculable
e
No chronic disease 1,190 70.2 19.4–89.0
Imputed data
f Crude
b All 2,902 82.8 68.6–90.6
,65 y 2,688 86.9 73.9–93.4
15–64 y 1,463 80.6 57.2–91.2
,15 y 1,218 94.2 75.6–98.6
No chronic disease 2,354 84.6 67.7–92.7
Adjusted model
d All 2,902 71.9 45.5–85.5
,65 y 2,688 78.4 54.3–89.8
15–64 y 1,463 73.3 36.7–88.7
,15y 1,218 84.8 31.0–96.6
No chronic disease 2,354 72.9 39.7–87.8
aExcluding individuals with missing values.
bStudy site included in the model as fixed effect.
cExact logistic regression estimates with zero cases vaccinated.
dModel adjusted for 2009–2010 seasonal influenza vaccination, any influenza vaccination in previous two seasons, presence of at least one chronic disease, sex, at least
one hospitalization for chronic disease in the previous 12 mo, current smoker, age group, practitioner visits in previous 12 mo (0, 1–4, and 5+ visits), month of
symptom onset (note: in the 15–64 y stratum no adjustment for age group; in the ‘‘no chronic disease’’ stratum no adjustment for chronic disease or hospitalizations
for chronic disease).
eIf one of the cases would have been vaccinated, the estimated PIVE would be 85.2% (95% CI 30.0–98.3).
fMissing data imputed using imputation using chained equations.
doi:10.1371/journal.pmed.1000388.t004
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differs from it since former influenza cases in the pandemic are not
excluded from potential controls (ILI testing negative).
In studies using the test-negative design, GPs may be more likely
to swab vaccinated ILI patients. In our studies the recruitment of
an ILI patient was not left to the GP’s decision. GPs from five out
of the seven sites used systematic sampling to recruit and swab ILI
patients. In Ireland practitioners were instructed to include five ILI
patients per week without applying a systematic selection
procedure. This could have introduced a selection bias if the
inclusion criteria were linked to the vaccination status and to the
case-control status. However, the participating practitioners in
Ireland recruited fewer than five cases per week, suggesting that
they recruited all patients consulting for ILI. In France, each
practitioner recruited a specific age group for the study. Thus, ILI
patients recruited may not have represented the age distribution of
the ILI population consulting participating practitioners. This
consideration could have biased the PIVE estimates if PIVE
differed by age group. However, ILI cases recruited in the study by
French participating practitioners have the exact same age
distribution as all ILI cases consulting them (unpublished data).
In addition, selection bias was further minimized since practition-
ers did not know the case or control status of the ILI patients at
time of recruitment.
Confounding
We limited the effect of potential confounding factors by
adjusting for most of the confounding factors described in the
Table 5. Pooled crude and adjusted PIVE, according to categories based on delay between date of vaccination and date of onset
of symptoms.
Crude and Adjusted
PIVE Estimates
Included
Population
Definition of Delay Vaccination—
Onset of ILI Symptoms n Percent PIVE 95% CI
Crude
a All ,8 d 1,502 20.6 2157.9 to 75.5
8–14 d 59.8 285.3 to 91.3
.14 d 79.2 56.3 to 90.1
,65 y ,8 d 1,367 15.7 218.1 to 74.7
8–14 d 57.6 297.6 to 90.9
.14 d 83.5 61.5 to 92.9
Adjusted model
b All ,8 d 1,502 18.8 2183.4 to 76.7
8–14 d 66.0 269.9 to 93.2
.14 d 66.9 26.0 to 85.2
,65 y ,8 d 1,367 15.5 2198.1 to 76.1
8–14 d 66.6 270.8 to 93.5
.14 d 72.0 30.8 to 88.7
aStudy site included in the model as fixed effect.
bModel adjusted for 2009–2010 seasonal influenza vaccine, any influenza vaccination in previous two seasons, presence of at least one chronic disease, sex, at least one
hospitalization for chronic disease in the previous 12 mo, current smoker, age group, practitioner visits in previous 12 mo (0, 1–4, and 5+ visits), month of symptom
onset.
doi:10.1371/journal.pmed.1000388.t005
Table 6. Pooled crude and adjusted 2009–2010 seasonal VE, multicentre case-control study, influenza season 2009–2010, seven
European Union study sites.
Complete Case and Imputed
Data Analysis
Crude and Adjusted
PIVE Estimates
Included
Population n
Percent
VE 95% CI
Complete case analysis
a Crude
b All 1,502 47.5 21.3 to 65.0
,65 y 1,367 47.0 14.0 to 67.4
Adjusted model
c All 1,502 9.9 265.2 to 50.9
,65 y 1,367 31.4 234.4 to 65.0
Imputed data
d Crude
b All 2,902 40.6 18.6 to 56.7
,65 y 2,688 25.6 27.3 to 48.4
Adjusted model
c All 2,902 21.5 267.0 to 38.3
,65 y 2,688 9.8 257.2 to 48.3
aExcluding individuals with missing values.
bStudy site included in the model as fixed effect.
cModel adjusted for 2009–2010 pandemic influenza vaccination, any influenza vaccination in previous two seasons, presence of at least one chronic disease, sex, at list
one hospitalization for chronic disease in the previous 12 mo, current smoker, age group, practitioner visits in previous 12 mo (0, 1–4, and 5+ visits), month of
symptoms onset.
dMissing data imputed using imputation using chained equations.
doi:10.1371/journal.pmed.1000388.t006
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the crude PIVE (absolute differences ranging from 7.3% to 12.8%)
suggesting some positive confounding. The main confounders
identified were time and age groups (Table S5). Time was
associated with vaccination status and outcome (lower vaccination
coverage and higher influenza incidence at the beginning the
study). During the influenza H1N1 pandemic, vaccination was a
time-dependent variable and the vaccine coverage observed
among controls increased over time. When splitting the study
period, the adjusted PIVE for both early and late phases was
above 68%. Further stratification of time was not possible due to
small numbers (i.e., two cases vaccinated in the early phase and ten
cases in the late phase).
In addition, the propensity to seek care and accept vaccination
may have changed over time during the pandemic. We controlled
for these potential changes by adjusting for month of onset of
symptoms. Adjusting for week of onset did not change the PIVE
estimates.
In the test-negative design the representativeness of the test-
negative controls has not yet been validated [11,17–20]. Some
studies suggest that vaccine coverage among ILI testing negative is
higher than in the community [10,17]. However community does
not represent the source population giving rise to cases because
vaccination coverage varies with health-seeking behaviour. The
test-negative design is believed to adjust for differences in health-
seeking behaviour between cases and controls. To further control
for this potential bias, we adjusted for the number of practitioner
visits in the previous 12 mo. However this adjustment may not be
appropriate if health-seeking behaviour differs between seasonal
and pandemic influenza.
One of the symptoms included in the EU ILI case definition is
the presence of sudden onset of symptoms: if vaccinated cases are
less likely to have sudden onset of symptoms and consequently less
likely to be recruited into the study than unvaccinated cases the
PIVE would be overestimated.
Overall if there is still residual confounding due to the above
factors we may still be overestimating PIVE.
Pooled Analysis
Even though the seven study sites shared a similar protocol, we
were unable to properly measure the heterogeneity between
studies owing to the small sample size at study-site level. We could
only use a one-stage pooling model that assumes that the effect
(PIVE) is the same in all the studies [21]. Heterogeneity between
studies may still exist as the result of the use of different vaccines,
different target groups, and a potential different health-seeking
behaviour. Therefore pooled estimates have to be interpreted with
caution.
Seasonal Vaccine
During the study period, the 2009–2010 seasonal vaccine seems
to have had no effect on pandemic H1N1 influenza illness. The
small number of ILI patients recruited in the $65 y age group and
the small number of vaccinated patients among the ,15-y-olds
precluded making robust VE estimates in these age groups. In our
study crude SIVE estimates are higher than adjusted SIVE
estimates. Methods suggested for controlling such positive
confounding include identifying an adjusted model leading to
0% VE before circulation of the virus and applying it to the
seasonal peak [22]. Those models are not applicable to laboratory-
confirmed outcomes.
Due to the controversial results of the effect of the 2008–2009
seasonal vaccine on pandemic H1N1-related outcomes [6,7,19], it
would have been interesting to estimate the VE of the 2009–2010
seasonal vaccine during the peak of the pandemic and before the
introduction of the pandemic vaccine; this was not done. In
addition, the small sample size in our study does not allow
measurement of any interaction between seasonal and pandemic
vaccines.
The good PIVE estimates we observed may be affected by the
test-negative design and its potential for bias and by the timing of
the studies in the late phase of the pandemic. As a consequence,
we cannot exclude that the PIVE we observed is overestimated.
Despite these limitations we believe that results from all seven
study sites are consistent in terms of the low number of vaccine
failures. The good PIVE found in the study corroborates the
strong immunogenicity results observed in clinical studies [1–3],
and the preliminary estimates of PIVE in Germany [23], Castello ´n
(Spain) [24], and Scotland [25].
In the past, similar studies using the test-negative design for
seasonal vaccines have documented estimates ranging from 34%
to 92% in seasons of good vaccine matching [10,11,17–20,26].
The pandemic estimates we observed in 2009–2010 fit in the
upper quartile of that distribution. However such a comparison is
complicated by potential differences in health-seeking behaviours,
age groups, and timing of studies.
This is the second year we have pilot tested a multicentre study
using the test-negative design. In future influenza seasons the
sample size per country will be enlarged in order to allow for
precise pooled and stratified analyses. In addition the use of
validation subsets, in which we collect more accurate and
additional information in a subsample of the ILI patients, will be
promoted.
I-MOVE is a unique network in Europe that is able to measure
seasonal and pandemic VE even in periods of high workload like
the 2009–2010 pandemic influenza season. On the basis of the
experience of the pilot phase in 2008–2009, and despite the low
pandemic vaccination coverage in the participating countries, the
results of the multicentre case-control study have provided early
estimates of the PIVE suggesting that the monovalent pandemic
vaccines have been effective. Our findings also provide an
indication of the VE for the A (H1N1) 2009 strain included in
the 2010–2011 seasonal vaccines. Specific VE studies will have to
be conducted to verify if similar good effectiveness estimates are
observed with the 2010–2011 trivalent vaccines.
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Background. Following the World Health Organization’s
declaration of pandemic phase six in June 2009,
manufacturers developed vaccines against pandemic
influenza A 2009 (pH1N1). On the basis of the scientific
opinion of the European Medicines Agency, the European
Commission initially granted marketing authorization to
three pandemic vaccines for use in European countries.
During the autumn of 2009, most European countries
included the 2009–2010 seasonal influenza vaccine and the
pandemic vaccine in their influenza vaccination programs.
The Influenza Monitoring Vaccine Effectiveness in Europe
network (established to monitor seasonal and pandemic
influenza vaccine effectiveness) conducted seven case-
control and three cohort studies in seven European countries
in 2009–2010 to estimate the effectiveness of the pandemic
and seasonal vaccines. Data from the seven pilot case-
control studies were pooled to provide overall adjusted
estimates of vaccine effectiveness.
Why Was This Study Done? After seasonal and pandemic
vaccines are made available to populations, it is necessary to
estimate the effectiveness of the vaccines at the population
level during every influenza season. Therefore, this study was
conducted in European countries to estimate the pandemic
influenza vaccine effectiveness and seasonal influenza
vaccine effectiveness against people presenting to their
doctor with influenza-like illness who were confirmed (by
laboratory tests) to be infected with pH1N1.
What Did the Researchers Do and Find? The researchers
conducted a multicenter case-control study on the basis of
practitioner surveillance networks from seven countries—
France, Hungary, Ireland, Italy, Romania, Portugal, and Spain.
Patients consulting a participating practitioner for influenza-
like illness had a nasal or throat swab taken within 8 days of
symptom onset. Cases were swabbed patients who tested
positive for pH1N1. Patients presenting with influenza-like
illness whose swab tested negative for any influenza virus
were controls.
Individuals were considered vaccinated if they had received
a dose of the vaccine more than 14 days before the date of
onset of influenza-like illness and unvaccinated if they were
not vaccinated at all, or if the vaccine was given less than 15
days before the onset of symptoms. The researchers
analyzed pandemic influenza vaccination effectiveness in
those vaccinated less than 8 days, those vaccinated between
and including 8 and 14 days, and those vaccinated more
than 14 days before onset of symptoms compared to those
who had never been vaccinated.
The researchers used modeling (taking account of all
potential confounding factors) to estimate adjusted vaccine
effectiveness and stratified the adjusted pandemic influenza
vaccine effectiveness and the adjusted seasonal influenza
vaccine effectiveness in three age groups (,15, 15–64, and
$65 years of age).
The adjusted results suggest that the 2009–2010 seasonal
influenza vaccine did not protect against pH1N1 illness.
However, one dose of the pandemic vaccines used in the
participating countries conferred good protection (65.5%–
100% according to various stratifications performed) against
pH1N1 in people who attended their practitioner with
influenza-like illness, especially in people aged ,65 years
and in those without any chronic disease. Furthermore, good
pandemic influenza vaccine effectiveness was observed as
early as 8 days after vaccination.
What Do These Findings Mean? The results of this study
provide early estimates of the pandemic influenza vaccine
effectiveness suggesting that the monovalent pandemic
vaccines have been effective. The findings also give an
indication of the vaccine effectiveness for the Influenza A
(H1N1) 2009 strain included in the 2010–2011 seasonal
vaccines, although specific vaccine effectiveness studies will
have to be conducted to verify if similar good effectiveness
are observed with 2010–2011 trivalent vaccines. However,
the results of this study should be interpreted with caution
because of limitations in the pandemic context (late timing
of the studies, low incidence, low vaccine coverage leading
to imprecise estimates) and potential biases due the study
design, confounding factors, and missing values. The
researchers recommend that in future season studies, the
sample size per country should be enlarged in order to allow
for precise pooled and stratified analyses.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000388.
N The World Health Organization has information on H1N1
vaccination
N The US Centers for Disease Control and Prevention
provides a fact sheet on the 2009 H1N1 influenza virus
N The US Department of Health and Human services has a
comprehensive website on flu
N The European Centre for Disease Prevention and Control
provides information on 2009 H1N1 pandemic
N The European Centre for Disease Prevention and Control
presents a summary of the 2009 H1N1 pandemic in Europe
and elsewhere
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